View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Analysis
December 1, 2021updated 11 Jul 2022 2:16pm

Asia-Pacific has seen the largest growth in haematological disorders related trials over the past decade

We've analysed 10 years' worth of clinical trials data from GlobalData to pick out key geographic trends.

By Saywah Mahmood

The Asia-Pacific region has seen a 158% increase in the number of haematological disorders trials taking place over the past decade, the largest increase for any region worldwide.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The region now ranks in first for the total number of trials taking place, compared to its fifth-placed ranking in 2010.

These figures come from GlobalData’s extensive clinical trials database which seeks to track the number of clinical trials taking place in countries around the world, in numerous therapy areas.

Asia-Pacific

The Asia-Pacific region saw the biggest increase in haematological disorders related trials.

Between 2010 and 2020, there was a 158% increase in the number of trials taking place.

In 2020, the largest proportion of trials in the region took place in China with 43.4% of all trials in the region taking place there.

India and Japan had the next largest percentage of trials taking place in the region with 13.2% and 10.4%, respectively.

Africa

Africa saw a 155% increase in the number of haematological disorders trials taking place.

Egypt saw the largest amount of trials taking place, in 2020, at 35.7%.

Trials in South Africa and Kenya also made up a large proportion of the trials taking place with 16.1% and 8.9%, respectively.

Middle East

The Middle East saw a 62% increase in the number trials taking place.

Iran, Israel and Saudi Arabia made up the most trials in the region, with 48.5%, 16.2% and 10.3%, respectively.

Europe

Europe saw a 22% increase in haematological disorders related trials taking place.

Italy saw the largest percentage of trials taking place in the region at 9.6%.

France and the United Kingdom also made up a significant proportion of the trials taking place.

North America

Despite being placed fifth, North America still saw an increase in the number of haematological disorders trials.

The region saw a 15% increase in the number of trials.

The United States made up 78% the largest proportion of trials taking place in the region.

Canada and Mexico also made up a large amount of the trials taking place with 17% and 4.9%, respectively.

South and Central America

South and Central America saw the biggest decrease in haematological disorders trials.

The number of trials in the region fell by 5% between 2010 and 2020.

Brazil saw the largest percentage of trials taking place in the region with 41%.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena